A Trial to Evaluate the Effects of Bifidobacterium Longum NCC3001 on Intestinal and Psychological Symptoms in Subjects With Irritable Bowel Syndrome

NACompletedINTERVENTIONAL
Enrollment

146

Participants

Timeline

Start Date

February 11, 2022

Primary Completion Date

December 4, 2024

Study Completion Date

February 14, 2025

Conditions
IBS - Irritable Bowel Syndrome
Interventions
DIETARY_SUPPLEMENT

Bifidobacterium longum

A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effects of Bifidobacterium Longum NCC3001 on Intestinal and Psychological Symptoms in Subjects With Irritable Bowel Syndrome

Trial Locations (11)

T2N 4Z6

University of Calgary, Calgary

T6G 2P8

University Of Alberta, Edmonton

A1B 3V6

Eastern Regional Health Authority, St. John's

P3C 1X3

Medicor Research Inc., Greater Sudbury

L8N 3Z5

McMaster University, Hamilton

P1B 2H3

Scott Shulman Medicine Professional Corporation, North Bay

K1H 8L6

The Ottawa Hospital General Campus, Ottawa

M3J 0K2

Canadian Phase Onward Inc., Toronto

G1V 4T3

Diex Recherche Quebec Inc., Québec

J6E 2B4

DIEX Recherche, Saint-Charles-Borromée

V8V 3M9

PerCuro Clinical Research Ltd., Victoria

All Listed Sponsors
collaborator

Syneos Health

OTHER

collaborator

Medidata Solutions

INDUSTRY

collaborator

McMaster University

OTHER

collaborator

CaligorRx, Inc.

UNKNOWN

lead

Société des Produits Nestlé (SPN)

INDUSTRY